Journal: The Journal of Allergy and Clinical Immunology. in Practice

Article Title: mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach

doi: 10.1016/j.jaip.2020.12.047

Figure Lengend Snippet: Risk stratification pathways with categories based on Mass General Brigham and Vanderbilt allergy expert consensus before initial COVID-19 vaccination. ∗If “yes” for questions 1 or 2, specific investigation as to the specific injectable products and vaccines should be pursued to determine whether these products could have contained high-molecular-weight PEG, polysorbate, or polyoxyl 35 castor oil (paclitaxel). See , , and . ¶Current CDC guidance suggests 30 minutes of observation for patients with any history of anaphylaxis. §See Figures 3 and for expanded skin testing procedures and non-irritating skin test concentrations. If skin testing to PEG is positive, as of December 28, 2020, Pfizer-BioNTech and Moderna are the only FDA approved vaccines and under EUA can not be given to an individual with a history of anaphylaxis to a component of the COVID-19 mRNA vaccine. Skin testing to polysorbate 20 and 80 become more important for patients with confirmed severe PEG allergy with regards to the safety of future vaccinations.

Article Snippet: The Pfizer-BioNTech EUA is for individuals 16 years and older, whereas Moderna is for individuals 18 years and older.

Techniques: Molecular Weight

Journal: Heliyon

Article Title: Sensitivity and specificity of in vivo COVID-19 screening by detection dogs: Results of the C19-Screendog multicenter study

doi: 10.1016/j.heliyon.2023.e15640

Figure Lengend Snippet: Demographic and anamnestic information of the subjects who received a nasopharyngeal swab at the drive-through center.

Article Snippet: Heterologous AstraZeneca/ Pfizer-BioNTech , , 11 , – , .

Techniques:

Journal: Human Vaccines & Immunotherapeutics

Article Title: Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review

doi: 10.1080/21645515.2023.2167410

Figure Lengend Snippet: Highest and lowest reported vaccine effectiveness (VE, with 95% confidence intervals) values of the COVID-19 vaccines against the Omicron variant in reducing infection as compared to the Delta variant.

Article Snippet: Compared to boosting 5 months prior to testing, Pfizer/BioNTech booster-VE against Omicron infection decreased each month from vaccination, with a peak VE of 53.4% (95% CI: 47.7–58.6) for those boosted just a month prior to testing versus a VE of 3.6% (95% CI: 0.6–6.5) for those boosted 4 months prior to testing.

Techniques: Variant Assay, Infection

Journal: Human Vaccines & Immunotherapeutics

Article Title: Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review

doi: 10.1080/21645515.2023.2167410

Figure Lengend Snippet: Highest and lowest reported vaccine effectiveness (VE, with 95% confidence intervals) values of the COVID-19 vaccines against the Omicron variant in reducing hospitalization as compared to the Delta and Alpha variants.

Article Snippet: Compared to boosting 5 months prior to testing, Pfizer/BioNTech booster-VE against Omicron infection decreased each month from vaccination, with a peak VE of 53.4% (95% CI: 47.7–58.6) for those boosted just a month prior to testing versus a VE of 3.6% (95% CI: 0.6–6.5) for those boosted 4 months prior to testing.

Techniques: Variant Assay

Journal: Human Vaccines & Immunotherapeutics

Article Title: Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review

doi: 10.1080/21645515.2023.2167410

Figure Lengend Snippet: Highest and lowest reported vaccine effectiveness (VE, with 95% confidence intervals) values of the COVID-19 vaccines against the Omicron variant in reducing the severity of infection as compared to the Delta variant.

Article Snippet: Compared to boosting 5 months prior to testing, Pfizer/BioNTech booster-VE against Omicron infection decreased each month from vaccination, with a peak VE of 53.4% (95% CI: 47.7–58.6) for those boosted just a month prior to testing versus a VE of 3.6% (95% CI: 0.6–6.5) for those boosted 4 months prior to testing.

Techniques: Variant Assay, Infection

Journal: Human Vaccines & Immunotherapeutics

Article Title: Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review

doi: 10.1080/21645515.2023.2167410

Figure Lengend Snippet: Highest and lowest reported vaccine effectiveness (VE with 95% confidence intervals) values of the COVID-19 vaccines against the Omicron variant in reducing mortality as compared to the Delta variant.

Article Snippet: Compared to boosting 5 months prior to testing, Pfizer/BioNTech booster-VE against Omicron infection decreased each month from vaccination, with a peak VE of 53.4% (95% CI: 47.7–58.6) for those boosted just a month prior to testing versus a VE of 3.6% (95% CI: 0.6–6.5) for those boosted 4 months prior to testing.

Techniques: Variant Assay

Journal: Viruses

Article Title: Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review

doi: 10.3390/v16121896

Figure Lengend Snippet: Pemphigus and BP following COVID-19 vaccination. BP: bullous pemphigoid; PV: pemphigus vulgaris (PV); PF: pemphigus foliaceus.

Article Snippet: Agharbi et al. [ ] , 1 , PV , 72, M , Pfizer/BioNTech Second dose , 7 , New onset.

Techniques: Membrane

Journal: Viruses

Article Title: Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review

doi: 10.3390/v16121896

Figure Lengend Snippet: Pemphigus and BP following COVID-19 vaccination. BP: bullous pemphigoid; PV: pemphigus vulgaris (PV); PF: pemphigus foliaceus.

Article Snippet: , , PV , 40, F , Pfizer/BioNTech First dose , 5 , New onset.

Techniques: Membrane